AstraZeneca and Eli Lilly are to continue with a pivotal phase 2/3 study of a key pipeline drug, AZD3293 for early Alzheimer's disease, after interim safety data boosted confidence in the d
UK-headquartered pharma company AstraZeneca has weighed into the debate about the country's place in the European Union, saying it supports staying in the trading bloc.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
